IAI Proudly Introduces TAA Tabletop Series Robots

IAI (Intelligent Actuator Incorporated), a leading robotics provider headquartered in Shizuoka, Japan, would like to introduce their TTA Tabletop Series robots. The accessible tabletop design provides an affordable “in-office” option for efficient and accurate patient testing and diagnosis.

“IAI is proud to be at the forefront of technology to assist the medical community in the battle against Covid-19 and any future health crisis,” says Kaz Haruna, National Sales Manager for IAI America. The current pandemic creates an urgent need for readily available multiple testing and diagnostic tools worldwide. The IAI Tabletop Series provides clients with customizable systems that are delivered complete and functional with minimal programming required on site. The compact design is flexible, precise, and multi-use to allow the user complete control over the required operation. The TTA series is also compatible with external video processing/analysis systems for micro-dosing applications.

Currently, IAI is actively assisting the medical community by providing robotic components for infectious disease testing, molecular diagnostics, tissue and blood sampling, genomic research, cancer research, pharmaceuticals, and medical device production.

About IAI: Founded in Shimizu, Japan in 1976, Intelligent Actuator Incorporated (IAI) has over forty years of experience in the design and manufacture of customized medical and industrial robotics. Built on “Quality and Innovation,” IAI is a leader in the research and development of advanced energy-efficient and affordable Cartesian, SCARA, and Tabletop robots. From entry-level to high-speed models, IAI provides complete programmable systems and components to fulfill any and all of your medical testing and industrial production needs.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”